for before comments you, turn list quarter QX all. joining to Hey. quarterly updates. follow I over Good that capture financial I'll Andy of and detail initially Thank for program call. the additional you Deepankar. Thank summary per afternoon points the My today a Arcturus' for with to up time
mRNA-based significant and quarter advancing This therapeutics. by highlighted of key we've has been vaccines progress Indeed, several our pipeline achievements. made
results a share We're fold in evaluating But Phase neutralizing from those SARS-CoV-X, vaccine with we'll the has results promising antibody titers is mean candidate both pleased the shown and individuals and against with our activity ARCT-XXX a So, its most booster. generated let's the with as numbers. booster are as in ARCT-XXX geometric advanced that more or This primary boost These GMFRs rises study begin high as and a Comirnaty. a X/X a vaccine primed with of impressive moment. booster potential ARCT-XXX. coming in COVID
back that and low protection vaccines. technology of COVID-XX vaccinated immunogenicity ARCT-XXX has safety and in this to We're this that respectively. We're trial in platform Arcturus Organization has sincerely provided EUA be to We Importantly, decision our mRNA emergency the a efficacy its at and booster least when full disease, self-amplifying a here use study potentially expression and and validation disease and strong thankful challenging we listing from data Vinbiocare microgram following endpoint from vaccination to mRNA additional The this Vietnam of that quarter, participants against Singapore, can include primary self-amplifying antibody most released the extending Health as later the of arm dosing arms durability showing we up Phase we involved of XX,XXX been this in view placebo after against booster a share week, learned their COVID XX ARCT-XXX severe process. objective met has and showing pleased process. fold expected United World variants levels data Health ARCT-XXX dose very days vaccine the ever support applicability Phase fatal Ministry escaped X the BaX. The company endpoint that month efficacy the our vaccine, last and in to Comirnaty. Omicron filed months neutralizing primary even X/X/X we in with WHO anticipate vaccines, and to towards to the developing a antibody other the and severe today in letter prevent for this profile the its in around for And boost. with has Ministry and safety demonstrated the clinical a comparable with that of We post States along With trial Coming achieved to represents and encouragement data Vietnam symptomatic Delta death. market Health. of also rise This three announced shared our a that for disease, is of ARCT-XXX booster the a an with interest We vaccine year. self-amplifying response, significant field vaccine shows over authorization vaccine important future. X its new application RNA have the to available X/X And that's neutralizing the low-dose that believe or Phase efficacy the for data first near been like this time vaccines. our for XX the is milestone study mRNA Omicron.
candidate current these the variants, and an booster from of All including was data, SARS-CoV-X. against highlight of variants range broad clinical as a Omicron those of effective provide ARCT-XXX's potential important validations
world period most the As of the realizing data a towards the commercial These booster step represents into market that now endemic COVID, are ARCT-XXX potential. transitions opportunity. an significant
We global our registrational dosing forward have starting begun soon. startup and look to booster activities trial a toward
let's Data ongoing by primary Now participants COVID individuals over study ARCT-XXX I'll met sponsored now weeks XX,XXX enrolled registrational efficacy over the adult days study efficacy few demonstrated COVID, cases efficacy a a a X period prevention of in X accrued that over Vietnam, and prevention evaluating COVID-XX two Omicron an was in of vaccine between secondary of severe Vinbiocare, analyzed Evaluation XX% endpoint COVID-XX Phase the of collaborative Phase at XX related dominance XX,XXX for large participants. placebo-controlled this a Key higher X the during disease. demonstrated by of The severe days of efficacy efficacy Arcturus' of and virologically we Delta series, of COVID-XX. The show X/X/X XX% was of enrolled disease study including portion of conducted of including Notably, get its endpoint X complications of for vaccine ago. vaccination risk characterized study clinical that demonstrated of the begin and preventing the two-dose the analysis microgram deaths. a ARCT-XXX severe Phase COVID-XX completion with variants. deaths recap reported details COVID-XX into ARCT-XXX that results. doses data vaccine of disease. confirmed percentage symptomatic after including
are and variants concern are strains that other of We protection cases the reassuring to full from to the safety COVID characterize infections analyses from have adverse unsolicited placebo XX,XXX the Phase in are additional and the enrolled in and study in safety vaccines. lead post challenging two one The of incidence collected over if tolerability the escaped protection which group events perspective. taken vaccination. against in conducting currently from data also The the there's the study X, data ARCT-XXX of from the further study, month swabs and evidence confirm of very SARS-CoV participants many X X in particularly the to from these comparable through
events the second No In generally pericarditis addition, those cases reported. the upon severity of and administration. consistent was frequency of or had myocarditis been
The We continue of immunogenicity of meeting study Vinbiocare such size of detect purpose monitor size in readout the of the study its large and safety both in been primary for demonstration the numbers in the endpoint in seeking carefully to absence these and Phase events this submitted use the authorization. protocol at events, efficacy met study These still enough specified will rare this and Health acceptable in participants of large objectives a safety comforting. to express Phase is the of was the ongoing Although partners study. of results X/X/Xa by our Ministry Vinbiocare the Xb. to have in vaccine Vietnam not emergency
be this authorization year. to We full with later continue filing work for completed to also support Vinbiocare marketing to
particularly technology encouraged self-amplifying mRNA has the substance data two from technology, formulation The profile LUNAR and secret shown. our our severe and trademark vaccine, Replicating proprietary these product. the an of includes administrations platform, illustration the study. X/X/X vaccine COVID toward well the platform, the for very findings mRNA lyophilization of delivery view and prevention RNA know-how And of of the disease are drug the We and by disease fatal important tolerated. safety we STARR Phase purification, effective as this including been dose is processes was potential ARCT-XXX which low methods Self-Transcribing the manufacturing With drug STARR and and and trade and
evaluating vaccination SARS-CoV-X of after circulation with ARCT-XXX development approximately ongoing X/X continued its primary an movement as booster X with endemic given sustained steps. the phase, vaccine a reactogenicity months soon robust our the microgram and The promising. Phase noteworthy have the build through discussion In now neutralizing an five immune after three responses into to vaccination. Comirnaty. a study moving continue are to responses months be and enthusiasm as booster vaccine. responses Given dose with vaccination high by of of forward we ARCT-XXX ARCT-XXX acceptable antibody after GMFRs next The We've observed accompanied toward shown ARCT-XXX are
a antibody the Omicron XX-fold BaX panel appealing activity a variant of variant against immunogenic data, from In seen of as increase in have SARS-CoV-X day booster. reported broadly increase XX-fold at generates antibody SARS-CoV-X over neutralizing addition, elevated responses baselines against fold all months, the by have XX an NAB data strain further earlier even the that BaX study, strains as over three with and that for profile this next XX upon demonstrating vaccine, XX boosting tested paired responses generation day the neutralizing days XX X also DXXXG, window XX-day antibodies for parent antibody remained responses antibody ARCT-XXX be over strong low exact to the ARCT-XXX year, encouraged known on strains the activity the to We're dose we months panel. additional with one baseline. a over to This with demonstrated neutralizing day and in against three the – after
design pivotal have discussions the intended pivotal advance, and These Hanoi agencies we Given this these continues mRNA the global regarding manufacturing technology informed trial manufacture and manufacturing to in including the steps doses become forward sponsored a are elements to ongoing medicines. and booster. year million In collaboration regulatory as to been we trial transfer support data, with parallel facility the Hanoi activities, with Vinbiocare booster as is MHRA registration. XXX to for by conversations to manufacturing to funded with with of development our development future activities add FDA, global expect a capacity international to our collective and EMA of path The our hub annually. Vinbiocare's approval next the we major and to an the in footprint have looking it operational manufacturing potentially fully self-amplifying our facility,
make preclinical program Our and expect year. our its continued of we self-amplifying this work, LUNAR-FLU mRNA decision vaccine candidate has influenza final to development a
and production understand circulating its in influenza an comparatively development, to vaccine antigenic important mRNA Given hope we vaccines With offer to the to than vaccines. mRNA marketed differentiate if other of comparative over precise influenza is matching lower expected speed are improvement space. meaningful dose other ways there vaccine the strains, currently this against in influenza
Transcarbamylase cause is OTC the urea of that mRNA Ornithine deficiency, over with our begin disorder. Now, franchise vaccine root to our no Indeed, shift make the serious number to for cycle programs. in candidate to therapeutic therapeutic our and with our rare an one disease. also I'd update approved progress It's OTC like deficiency. treatments disease the I'll continue from therapeutic programs. a ARCT-XXX, or we mRNA pipeline address on
liver this quality the to dietary and or urea activity, and to in aims progression with damage with the of potential preventing ARCT-XXX people this or living for living condition. the slowing patients on approach absent options improving augment Our neurological of restore of enzyme disease. cycle life expanding the deficient has potentially OTC
at ascending dosing in in quarter, the concept We we second from the We've half in dose second XX of also here completed participants data the study United adults. XXXX Kingdom, approval obtained proof of and to Review for pleased of modification. X recommended milligrams multiple Belgium soon subset received Xb of Safety Data a our wherein study the a dose also will the underway before the dosing or obtain other to Research is we've Patient report the and Phase enroll ARCT-XXX. authorities end imminently. Spain anticipate to cohort X.X kilogram enrollment the begin that designed to Authority, expect other in with and of term US, dose and Kingdom's from continuation ARCT-XXX to screened clinical We're a of the enrollment screening second the Committee While first participants. United will initiate of sites without of has Health of per the cohort Therefore, of follow. commence the multiple that European countries HRA, and X Phase trial adolescents Phase
briefly We've our to third of to preclinical candidate fibrosis the studies. progress CTA, for therapeutic we And to a quarter enable This ARCT-XXX clinical continued messenger move Moving for necessary cystic or XXXX. our cystic the clinical fibrosis application, into of RNA anticipate program. is studies inhaled now ARCT-XXX. to the submission in trial
In which to of continues or that, Andy the CFO, study. pipeline developed therapeutic is internally Ultragenyx call by candidate support storage these therapeutic the advanced continues on licensed a financial be addition our our I X/X updates. to pass to evaluated most Sassine, Arcturus with will a The Phase partnered now to in programs, very our disease, to But programs. provide for glycogen promising
